Search Results

As AAV9 and CRISPR programs navigate safety, delivery and scalability hurdles, small molecules offer a deployable, scalable bridge, complementing genetic approaches and accelerating meaningful impact for patients with Duchenne muscular dystrophy.

This webinar examines how immune memory in allergic individuals may offer new therapeutic possibilities. Pr. Pierre Bruhns presents his team’s research on characterizing antibody repertoires specific to the neuromuscular blocker rocuronium. Discover how these antibodies contribute to anaphylactic reactions and how they could support the development of diagnostic tools and therapeutic agents to reverse neuromuscular blockade.

Albert Bourla heralded the president’s COVID-19 leadership and Operation Warp Speed initiative as a Nobel Prize–worthy achievement and said that Pfizer stands by the integrity of the data already shared.

In a series of memos last week, Center for Biologics Evaluation and Research Director Vinay Prasad outlined the FDA’s thinking on the recent limited approvals for updated COVID-19 vaccines.

In an opinion piece in the Wall Street Journal, Health Secretary Robert F. Kennedy Jr. said he will roll chronic disease programs into a new Administration for a Healthy America.

Export of 1,000 natural psilocybin capsules for prescription use under Australia’s Authorised Prescriber Scheme follows the Company’s successful launch of MDMA sales in 2024